Biotech Stocks off to an Early Lead in 2017

I like paying attention to what moves quickly out of the gate come the new year.

In 2016, we were in a spiral lower, so correlations were high and “sell everything” was the only thing we needed to know for the first 30 days.

This year, we’re in a stable uptrend and can make note of early out-performers for clues to new or persisting trends.

It’s only been two days but biotech stocks are already up nearly 5% and have cleared through December resistance around 275.

The longer term weekly chart tells a story of consolidation as we spent the entire year in 2016 trading between 245 and 295 , a 50 point 20% range.

If we can get a strong weekly close north of 275 that could pave the way nicely for a re-test of this long term $295 resistance.

Some of those big cap components that make up a large piece of this ETF like $AMGN $GILD $BIIB look equally encouraging for a bounce/move higher.

We hold no positions in any of the above at this time.

Thanks for reading and good luck out there.

Enjoy what you read? Share it below and be sure to tag @thetraderisk.

Find similar content on the following:
Posted in ,
Tagged with

Evan Medeiros

Evan is the founder of the Trade Risk. With 25 years of coding experience and a B.S. in computer science, Evan brings a systematic discipline to investing in the stock market.

Don't miss out on more educational articles just like this!

Please enter your name.
Please enter a valid email address.
Something went wrong. Please check your entries and try again.

Leave a Comment